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Introduction
There is experimental evidence that tumour growth is
dependent on angiogenesis. This process is fundamental
in tumour growth, progression, and metastases [1, 2].
Intratumoral microvessel density is assumed to
reflect the intensity of tumour angiogenesis [3]. In breast
[4, 5], prostate [6], ovarian [7], rectal [8] and gastric
carcinomas [9] high vascular density (VD) is associated
with shorter survival. In NSCLC, the correlation between
worse prognosis and high VD was found in most studies
[10-12], however not in all [13, 14].
The analysis of vascular density in the homogenous
group of SqCLC is justified, as it was found that vascular
density in adenocarcinomas is higher than in SqCLC [15-
17], thus possibly indicating the different biology of those
two groups of NSCLC.
Recently, new anti-angiogenic drugs are being tested
in clinical trials [18].
We have decided to study the vascular density in
surgically treated SqCLC patients.
Material and methods
Pa t i e n t s
Between 1986 and 1996, 40 SqCLC patients (36 men and 4
women) were treated with radical surgery: 22 underwent
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I n t r o d u c t i o n.  Neo-angiogenesis is a fundamental element of tumour growth, progression and metastases. Opinions in
literature differ as to the prognostic significance of vascular density (VD) in non-small cell lung cancer (NSCLC).
M a t e r i a l  a n d  m e t h o d s we analysed VD in 40 patients treated surgically for squamous cell lung cancer (SqCLC). The
FVIII in endothelial cells was visualized on formalin fixed, paraffin embedded sections, using immunohistochemical
methods.
R e s u l ts.  The mean value of VD was 37.5±2.5. Patients high VD tumours (VD>39 vessels/mm2) achieved significantly
shorter survival than those with low VD (VD≤39 vessels /mm2), p=0.0279.
C o n c l u s i o n.  VD should be considered in the assessment of prognostic parameters for NSCLC.
WartoÊç prognostyczna g´stoÊci unaczynienia u chorych 
na p∏askonab∏onkowego raka p∏uc leczonych operacyjnie
W s t ´ p.  Angiogeneza jest jednym z podstawowych procesów odpowiedzialnych za wzrost nowotworu, jego progresj´
i tworzenie przerzutów. W literaturze brak jest zgodnoÊci w kwestii prognostycznej wartoÊci g´stoÊci unaczynienia (GU)
u chorych na niedrobnokomórkowego raka p∏uc.
M a t e r i a ∏  i m e t o d y.  GU oceniono w grupie 40 chorych na p∏askonab∏onkowego raka p∏uc, leczonych operacyjnie.
FVIII zosta∏ uwidoczniony w komórkach Êródb∏onka naczyƒ, na utrwalonych w formalinie skrawkach parafinowych, przy
u˝yciu immunohistochemii.
W y n i k i.  Ârednia GU wynosi∏a 37,5±2,5. Chorzy na nowotwory o du˝ej GU (GU>39 naczyƒ/mm2) prze˝ywali istotnie krócej
ni˝ chorzy na nowotwory o ma∏ej GU (GU≤39 naczyƒ /mm2), p=0,0279.
W n i o s e k.  Parametr, jakim jest GU, powinien byç brany pod uwag´ przy ocenie czynników prognostycznych u chorych na
niedrobnokomórkowego raka p∏uc.
Key words: squamous cell lung cancer, vascular density, prognostic significance
S∏owa kluczowe: p∏askonab∏onkowy rak p∏uca, g´stoÊç unaczynienia, wartoÊç prognostyczna
1 Laboratory of Radiation Biology
2 Department of Oncological Surgery
3 Diagnostic Radiology Department
Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology, Cracov Branch, Poland
lobectomy and 18 – pneumonectomy. Mean patient age was
58.5±1 yr.
Before surgery the patients did not receive radio- or
chemotherapy. There were 20 stage I, 14 – stage II and 6 –
stage IIIa patients. Each patient was followed-up for 5 years
after surgery. Seventeen patients died: 4 because of loco-
regional cancer recurrence and 13 due to distant metastases.
Twenty-three patients are still alive without progression of
SqCLC.
Methods
Fresh tumour specimens (approx. 0.5 cm2) were delivered from
the operating room, shortly after excision. All specimens were
fixed in 10% neutral buffered formalin and embedded in
paraffin.
S t a i n i n g  p r o c e d u r e s
Sections were cut at 4 µm, mounted on Super Frost® Plus
(Menzel – Gläser, Germany) slides, and then deparaffinized
and hydrated through a series of xylens and alcohols.
Endogenous peroxidase activity was blocked by H2O2 in
methanol. Before staining, the sections were digested for 25
minutes at room temperature with 0.01% solution of trypsin
(pH 7.8). Next, sections were incubated (15 minutes, room
temperature) with 20% swine serum (normal), (DAKO Ltd.).
Von Willebrand Factor was detected using rabbit anti-human
von Willebrand factor (purified immunoglobulin fraction of
rabbit antiserum), (DAKO Ltd.) diluted 1/400 in TBS (pH 7.4),
(1 hour incubation, 37°C). Next, slides were incubated with
secondary biotynylated antibody (DAKO Ltd.) diluted 1/800
and with avidin and biotinylated horseradish peroxidase complex
(DAKO Ltd.), (30 minutes incubation at room temperature for
both incubations). Diaminobenzidyine and H2O2 were used to
visualise peroxidases (10 minutes at room temperature). In the
end, slides were counterstained with hematoxylin. For negative
control, rabbit serum (normal) (DAKO Ltd.) was substituted
for the primary antibody.
M i c r o v a s s e l  g u a n t i f i c a t i o n
Vessel density (VD) was assessed at ×500 magnification (×40
objective lens and ×12.5 ocular lens; 0.145 mm2 per field) in 7
randomly selected fields. The archival tissue sections included
into analysis were of different size. In case of small samples it
was impossible to find „hot spots”. Therefore we decided to
apply a method based on the assessment of VD in randomly
selected fields for all slides. VD was expressed as a mean (of 7
values) number of vessels per 1 mm2.
Any brown-stained endothelial cell or endothelial cell
cluster that was clearly separated from adjacent microvessels,
tumour cells and connective tissue elements, was considered as
a single, countable vessel (Figure 1A). Vessel lumen was
not necessary for defining a structure as a microvessel [4]. VD
was assessed only in tumour tissue (Figure 1A). Vessels located
near normal tissue structures were excluded from analysis
(Figure 1B).
S t a t i s t i c a l  a n a l y s i s
Descriptive statistics were used to determine mean values of
VD and standard errors of mean (SE). In all statistical
procedures, α<0.05 was considered significant. The statistical
significance of the differences between the mean values was
assessed by Mann-Witney U test. Disease-specific survival (the
patients whose cause of death was not malignant were treated as
alive) was analysed. The probability of survival was calculated
using the Kaplan – Meyer method. Univariate analysis was
performed using the log-rang test. As neither median nor mean
value was statistically significant, we determined an optimal cut-
off point (39 vessels /mm2) for the VD variable (‘minimal’ p
value) by the log-rank test.
Results
In the analysed group of 40 SqCLC vessels were mainly
located at the margins of large tumour nests (Figure 1A)
and, sometimes, the microvessels penetrated into the
central portions of those tumour nests. Vessels located
near normal tissue structures were of larger size and
sometimes were stained more strongly with anti-FVIII
than tumour microvessels (Figure 1B).
VD ranged between 6.9 – 78.8 microvessels/mm2,
with a mean value of 37.5±2.5 and a median of 34.2. No
differences in mean values of VD were found between the
different stages of the tumours. There was no correlation
between patient age and VD (p=0.3).
The Kaplan-Meier estimated 5-year disease-specific
survival was 54%. Patients having tumours with high VD
(VD>39 vessels/mm2) achieved significantly shorter
survival than those with low VD (VD≤39 vessels /mm2),
p=0.0279, (Figure 2, Table I).
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Figure 1. Vessels (indicated by arrows) in tumour tissue (A) and near
normal tissue structures (B), (×160)
Discussion
The mean VD observed in our study remains within the
broad range of other authors’ results (Table II). Table II
illustrates that there is no standardisation of VD
assessment methods and hence the VD values and their
prognostic significance vary in different reports. Dis-
crepancies might be caused by different antibodies used,
different methods of VD assessment, and histological
heterogeneity of analysed NSCLC groups (Table II).
The choice of the optimal method for VD measu-
rement remains a matter of discussion. Several studies
have proven that anti-FVIII microvessel staining may be
imprecise for several reasons: (1) FVIII is present in the
lymphatic endothelium and in the platelets [20]. (2) In
addition, when using anti-FVIII, newly formed vessels
cannot be distinguished from older ones [20]. (3)
However, the most important fact is that FVIII is not
expressed in all endothelial cells, because endothelial
cells of microvessels are less rich in Weibel-Palade bodies,
than those of macrovessels [20]. Also, the endothelial
cells of neocapilaries, when activated by cytokins (like
thrombin and intrrleukins), may release their FVIII stores
[20]. In our study we observed large or medium sized
vessels to be stained stronger with anti-FVIII than
microvessels. In other studies, [26] small vessels clearly
defined in the anti-CD31 stained slides were less
frequently defined in the anti-FVIII-stained slides (large
or medium sized vessels were well stained with both
antibodies). Besides, in a number of studies [15, 20, 21, 26,
27] the vascular density assessed using anti-FVIII
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Figure 2. Correlation between vascular density (VD) and disease
specific survival. Survival as a function of VD stratified using the
VD≤39 vessels/mm2 and the VD≤39 vessels/mm2
Table I. Univariate analysis for SqCLC patients treated 
with surgery.
Data for 5-year disease-specific survival
parameter n Median The Kaplan-Meier (log- rank 
survival estimated 5-year test)
(months) survival (%) p value
VD
VD≤39vessels/mm2 23 - 67
VD>39vessels/mm217 15 36 0.0279
Table II. Prognostic significance of vascular density in NSCLC and methods of VD assessment. Literature data
Author, year of publication No. of Antibody Survival Method of VD assessment (magnification) Mean (median) 
patients number  of vessels 
per mm2 of sample
Masuya et al. 2001 [17] 104 Anti-CD34 S Average of the 3 „hot spots” (200×) 125.0± 62.8
Cagini et al. 2000 [19] 99 Anti-CD34 NS Average of the 3 „hot spots” (250×) 50.0±17.7
Yano et al. 2000 [20] 108 Anti-FVIII NS Sum of the vessel count of 4 „hot spots” (200×) 11.9±5.5
Anti-CD34 S 19.3±6.9
Mattern et al. 1999 [14] 87* Anti-FVIII NS Average of the 3 „hot spots” (250×) 16.5 (median)
Duarte et al. 1998 [21] 112 Anti-FVIII S Average of the 2 „hot spots” (200×) 28.0±15.1
Anti-CD31 NS 40.0±24.5
Matsuyama et al. 1998 [12] 101 Anti-CD34 S Average of the 3 „hot spots” (200×) 96.1±63.6
Apolinario et al. 1997 [10] 104 Anti-CD31 NS** Sum of the vessel count of 4 „hot spots” (400×) 106.9± 41.7
Chanrachud et al. 1997 [13] 88 Anti-FVIII NS “hot spot” with highest number of microvessels (200×) 140.8
Average of 18 randomly selected fields (200×) 67.2
Fontanini et al. 1997 [22] 407 Anti-CD34 S Average of the 3 „hot spots” (250×) 27.0 (median)
Fontanini et al. 1997 [11] 73 Anti-FVIII S “hot spot” with highest number of microvessels (250×) 19.2 (median)
Lucchi et al. 1997 [23] 227 Anti-CD-34 S “hot spot” with highest number of microvessels (200×) 29.2±19.0
Angeletti et al. 1996 [24] 96 Anti-FVIII S “hot spot” with highest number of microvessels (200×) 36.7±18.9
Fontanini et al. 1995 [25] 253 Anti-FVIII S “hot spot” with highest number of microvessels (250×) 62.0±36.3
S – significant
NS – not significant
* SqCLC
** significant only for stage II patients
antibody was lower than when assessed with other
endothelial cell markers (anti–CD31, CD-34 or PECAM).
Additionally, no correlation was found between anti-
FVIII and anti- CD-34 – defined VD [20] or between
anti-FVIII and anti- CD-31 – defined VD [21]. These
results indicate that anti-FVIII is a less sensitive marker of
tumour vascularisation, which, in turn, suggests that other
antibodies (anti-CD31, anti-CD34) should be recom-
mended for VD assessment. Despite that, the progno-
stic significance of VD was found using both anti-FVIII
and anti-CD31 or CD34 antibodies (Table II). In our
study, VD assessed using anti-FVIII was also found to
influence patient survival significantly.
The assessment of VD in randomly selected fields
(as in our study) is rarely used by other authors [13]
(Table II). However, in some studies, VD assessed using
the “hot spot” method was not associated with patient
survival [10, 13, 14, 20, 21]. The fact that in our study
VD was a prognostic parameter might indicate that the
assessment of VD in randomly selected fields might be an
alternative for the “hot spot” method.
Concluding, VD should be taken into consideration
during the assessment of prognostic parameters for
NSCLC.
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